ProBio

ProBio, founded in 2020, and headquartered in the United States, is a global contract development and manufacturing organization (CDMO) poised at the forefront of the biopharmaceutical industry. With its slogan, "Manufacturing Life-Changing Therapies," ProBio focuses on accelerating the production of transformative drugs.

With expertise spanning Biopharma, Biotechnology, Life Sciences, and the Pharmaceutical sector, ProBio excels in developing therapeutics based on DNA, RNA, and proteins. Their services encompass biologics, protein and mRNA vaccines, viral vectors, antibody-drug conjugates, and drug discovery, which underline their capability to streamline market entry for pioneering medical discoveries.

ProBio's absence of recent investment activities suggests a focus on operational scalability and strategic industry partnerships. Their integrated approach and global reach position them as a crucial partner for innovators aiming to translate groundbreaking discoveries into viable, market-ready therapeutics.